piracetam has been researched along with Liver Diseases in 7 studies
Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent.
Liver Diseases: Pathological processes of the LIVER.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to evaluate the risk factors, clinical implications, and prognosis of new-onset seizures that occurred after pediatric liver transplantation, and to assess the efficacy of levetiracetam treatment." | 7.85 | Seizures in Pediatric Patients With Liver Transplant and Efficacy of Levetiracetam. ( Arslan, M; Güngör, S; Kılıç, B; Selimoğlu, MA; Yılmaz, S, 2017) |
| " In Phase II/III trials, the adverse effects occurring more commonly in the treatment groups versus the placebo group were; somnolence (14." | 6.42 | Levetiracetam safety profiles and tolerability in epilepsy patients. ( Briggs, DE; French, JA, 2004) |
| "The aim of this study was to evaluate the risk factors, clinical implications, and prognosis of new-onset seizures that occurred after pediatric liver transplantation, and to assess the efficacy of levetiracetam treatment." | 3.85 | Seizures in Pediatric Patients With Liver Transplant and Efficacy of Levetiracetam. ( Arslan, M; Güngör, S; Kılıç, B; Selimoğlu, MA; Yılmaz, S, 2017) |
| " Pharmacokinetic studies of levetiracetam have been conducted in healthy volunteers, in adults, children and elderly patients with epilepsy, and in patients with renal and hepatic impairment." | 2.42 | Clinical pharmacokinetics of levetiracetam. ( Patsalos, PN, 2004) |
| " In Phase II/III trials, the adverse effects occurring more commonly in the treatment groups versus the placebo group were; somnolence (14." | 2.42 | Levetiracetam safety profiles and tolerability in epilepsy patients. ( Briggs, DE; French, JA, 2004) |
| "Levetiracetam is a novel orally active antiepileptic drug with a unique preclinical profile." | 2.41 | Pharmacokinetic profile of levetiracetam: toward ideal characteristics. ( Patsalos, PN, 2000) |
| " The results of these studies indicate that higher doses need to be used for children (on a per-weight basis), and individuals with renal dysfunction require dosage modifications related to creatinine clearance." | 2.41 | Use of levetiracetam in special populations. ( French, J, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (14.29) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (57.14) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kılıç, B | 1 |
| Güngör, S | 1 |
| Arslan, M | 1 |
| Selimoğlu, MA | 1 |
| Yılmaz, S | 1 |
| Ghosh, P | 1 |
| Motamedi, G | 1 |
| Osborne, B | 1 |
| Mora, CA | 1 |
| Patsalos, PN | 2 |
| Briggs, DE | 1 |
| French, JA | 1 |
| French, J | 1 |
| Sokolova, GB | 1 |
| Nikolaev, VP | 1 |
| Braude, VI | 1 |
| Ziia, AV | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Study of Pharmacokinetics of Levetiracetam in Patients Undergoing Intermittent Hemodialysis[NCT04511676] | 12 participants (Actual) | Observational | 2018-11-01 | Completed | |||
| Lamotrigine Versus Levetiracetam in the Initial Monotherapy of Epilepsy: An Open, Prospective, Multicenter, Randomized Phase III Study[NCT00242606] | Phase 3 | 409 participants (Actual) | Interventional | 2005-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for piracetam and Liver Diseases
| Article | Year |
|---|---|
Clinical pharmacokinetics of levetiracetam.
Topics: Adult; Aged; Anticonvulsants; Chemical Phenomena; Chemistry, Physical; Child; Drug Interactions; Dru | 2004 |
Levetiracetam safety profiles and tolerability in epilepsy patients.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Age Factors; Aged; Animals; Anticonvulsants; Astheni | 2004 |
Pharmacokinetic profile of levetiracetam: toward ideal characteristics.
Topics: Absorption; Adolescent; Adult; Aged; Anticonvulsants; Child; Cytochrome P-450 Enzyme System; Drug In | 2000 |
Pharmacokinetic profile of levetiracetam: toward ideal characteristics.
Topics: Absorption; Adolescent; Adult; Aged; Anticonvulsants; Child; Cytochrome P-450 Enzyme System; Drug In | 2000 |
Pharmacokinetic profile of levetiracetam: toward ideal characteristics.
Topics: Absorption; Adolescent; Adult; Aged; Anticonvulsants; Child; Cytochrome P-450 Enzyme System; Drug In | 2000 |
Pharmacokinetic profile of levetiracetam: toward ideal characteristics.
Topics: Absorption; Adolescent; Adult; Aged; Anticonvulsants; Child; Cytochrome P-450 Enzyme System; Drug In | 2000 |
Use of levetiracetam in special populations.
Topics: Adult; Age Factors; Aged; Anticonvulsants; Child; Comorbidity; Contraceptives, Oral; Drug Approval; | 2001 |
3 other studies available for piracetam and Liver Diseases
| Article | Year |
|---|---|
Seizures in Pediatric Patients With Liver Transplant and Efficacy of Levetiracetam.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Electroencephalography; Female; Humans; Infant | 2017 |
Reversible blindness: simple partial seizures presenting as ictal and postictal hemianopsia.
Topics: Adult; Anticonvulsants; Brain; Electroencephalography; Epilepsies, Partial; Female; Hemianopsia; Hum | 2010 |
[Drug prophylaxis of liver lesions induced by isoniazid and its metabolites].
Topics: Animals; Butylated Hydroxytoluene; Chemical and Drug Induced Liver Injury; Female; Inosine Diphospha | 1989 |